– Interview with George Calin, M.D., Ph.D., Associate Professor, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center

Previous articleEMD and Merck Serono to Fork Out $50M for New Research Center in Massachusetts
Next articleArtes Biotechnology Produces Virus-Like Particles for Select Vaccines from a Yeast-Based System